Fc-mediated mechanisms complement-dependent cytotoxicity (CDC) is considered to be particularly important for successful therapeutic intervention. Creative Biolabs is proud to offer our global customers a novel CDC enhanced antibody production technology named Crea-Tag™, which has been confirmed to significantly enhance the CDC effect of antibodies.
In complement-dependent cytotoxicity (CDC), C1q binds to antibodies, triggering the complement cascade, resulting in the formation of a membrane attack complex (MAC) (C5b to C9) on the surface of target cells, further leading to classical pathway complement activation. Among these factors attributable to CDC resistance, soluble regulatory complement factor H (CFH) was found to fail to activate complement-dependent cytotoxicity (CDC).
Functions of factor H are as follows:
We have developed a Crea-Tag™ protein which can be coexpressed as a fusion protein with any antibody. By displacing the CFH on tumor cells, it can activate complement-mediated lysis.
Crea-Tag™ antibody modifications include:
Fig.2 Mode-of-action: Crea-Tag displaces the CFH on tumor cells.
For more detailed information, please feel free to contact us or directly sent us an inquiry.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.